Lupin has claimed to have passed the UK health regulator inspection of its Goa facility without making any critical observations.
In a BSE filing, Lupin announced the successful completion of the inspection by the UK MHRA at its Goa facility in March 2018. There were no critical or major observations in the inspections.
Lupin Managing Director Nilesh Gupta said, “We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant.”
Lupin had lately announced clearance from Health Canada after a review of its Pithampur unit 2 manufacturing facility located in Indore.
In November 2017, Lupin had received a warning letter from the US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
Shares of Lupin were trading up by 1.68 per cent at Rs 788.40 on the BSE.
